Familial and acquired hemophagocytic lymphohistiocytosis

Clicks: 280
ID: 115086
2006
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #11 of 16 articles by views in European journal of pediatrics

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition of severe hyperinflammation caused by the uncontrolled proliferation of activated lymphocytes and histiocytes secreting high amounts of inflammatory cytokines. Cardinal signs and symptoms are prolonged fever, hepatosplenomegaly and pancytopenia. Characteristic biochemical markers include elevated triglycerides, ferritin and low fibrinogen. HLH occurs on the basis of various inherited or acquired immune deficiencies. Impaired function of natural killer (NK) cells and cytotoxic T-cells (CTL) is shared by all forms of HLH. Genetic HLH occurs in familial forms (FHLH) in which HLH is the primary and only manifestation, and in association with the immune deficiencies Chédiak-Higashi syndrome 1 (CHS 1), Griscelli syndrome 2 (GS 2) and x-linked lymphoproliferative syndrome (XLP), in which HLH is a sporadic event. Most patients with acquired HLH have no known underlying immune deficiency. Both acquired and genetic forms are triggered by infections, mostly viral, or other stimuli. HLH also occurs as a complication of rheumatic diseases (macrophage activation syndrome) and of malignancies. Several genetic defects causing FHLH have recently been discovered and have elucidated the pathophysiology of HLH. The immediate aim of therapy in genetic and acquired HLH is suppression of the severe hyperinflammation, which can be achieved with immunosuppressive/immunomodulatary agents and cytostatic drugs. Patients with genetic forms have to undergo stem cell transplantation to exchange the defective immune system with normally functioning immune effector cells. In conclusion, awareness of the clinical symptoms and of the diagnostic criteria of HLH is crucial in order not to overlook HLH and to start life-saving therapy in time.
Reference Key
janka2006europeanfamilial Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Gritta E. Janka;Gritta E. Janka;
Journal European journal of pediatrics
Year 2006
DOI
doi:10.1007/s00431-006-0258-1
URL
http://dx.doi.org/10.1007/s00431-006-0258-1
Keywords
Pediatrics immunity National Center for Biotechnology Information NCBI NLM MEDLINE review diagnosis humans pubmed abstract nih national institutes of health national library of medicine risk factors differential lymphohistiocytosis cytokines / metabolism genetic predisposition to disease cell proliferation t-lymphocytes / metabolism t-lymphocytes / immunology* cellular* pmid:17151879 doi:10.1007/s00431-006-0258-1 gritta e janka hemophagocytic* / genetics hemophagocytic* / immunology hemophagocytic* / pathology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.